Korro Bio (NASDAQ:KRRO) reported quarterly losses of $(2.49) per share which beat the analyst consensus estimate of $(2.61) by 4.6 percent. This is a 2.05 percent decrease over losses of $(2.44) per share from the same period last year. The company reported quarterly sales of $2.55 million which beat the analyst consensus estimate of $180.00 thousand by 1.32K percent.